All In Biotech

Drug Trial Radar · NCT04355858

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Precision Treatment of Luminal Advanced Breast Cancer Based on Molecular Subtyping

Last checked: Nov 20, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

319

Planned (sponsor's estimate)

Start

May 1, 2020

Primary completion

May 1, 2023

Study completion Apr 1, 2025

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, single-center, open-label, umbrella-shaped phase II clinical study for patients with HR+/HER2- endocrine-resistant advanced breast cancer.

Conditions

  • Breast Cancer
  • Metastatic Cancer

Interventions

  • SHR7390Drug

    MEK1/2 inhibitor

  • FamitinibDrug

    Multi-target tyrosine kinase inhibitor

  • SHR3162Drug

    PARP inhibitor

  • PyrotinibDrug

    HER1 / HER2 receptor tyrosine kinase inhibitor

  • CapecitabineDrug

    In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.

  • SHR1210Drug

    PD-1 antibody

  • EverolimusDrug

    mTOR inhibitor

  • Nab paclitaxelDrug

    Albumin bound paclitaxel

  • SHR2554Drug

    EZH2 inhibitor

  • SHR3680Drug

    AR inhibitor

  • SHR6390Drug

    CDK4/6 inhibitor

  • SHR1701Drug

    anti-PD-L1/TGF-βRII bifunctional fusion protein

  • SERDDrug

    Fulvestrant

  • AIDrug

    aromatase inhibitor

  • VEGFiDrug

    Bevacizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.